Nina V. Tsvetaeva

Nina V. Tsvetaeva

Auto-generated profile, based on publicly available information

Nina V. Tsvetaeva

National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2022 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
GGGennadiy Galstyan
Gennadiy Galstyan
RSR. G. Shmakov
R. G. Shmakov
ЕKЕ. Е. Klebanova
Е. Е. Klebanova
VTV. V. Troitskaya
V. V. Troitskaya
VDV. N. Dvirnyk
V. N. Dvirnyk
ЮПЮ. М. Познякова
Ю. М. Познякова
Introduction. Pregnancy is one of the most frequent triggers of congenital and acquired forms of thrombotic thrombocytopenic purpura (TTP).Aim — to develop tactics for the treatment of pregnant women with TTP.Results. TTP was associated with pregnancy in 55.5 % of all cases of TTP in women. In 5 pregnancies in which the diagnosis of TTP was known before pregnancy, or established in the early stages, TTP was treated throughout the pregnancy. In the congenital form, plasma transfusions were performed once every two weeks until the 20th week of pregnancy, or weekly, if thrombocytopenia < 150 × 109 /L persisted. Plasma transfusions were performed weekly after the 20th week with the goal of achieving clinical remission. With acquired TTP, glucocorticosteroids and plasma exchanges were used as treatment, in 1 case — rituximab, with the aim of achieving a clinical remission and an ADAMTS13 activity > 20 %. In this group of pregnant women, 1 caesarean section was performed and there were 4 cases of vaginal deliveries, with a total of 5 children being born with an average Apgar score of 7.5. In 7 pregnancies in which TTP fi rst manifested late, leading to a delayed diagnosis, preventive and curative measures were not carried out before delivery. In this group there were 2 abortions of pregnancy, 5 surgical deliveries, 3 cases of preeclampsia, 3 acute cerebral circulatory disorders, 1 intraabdominal bleeding, 1 case of acute renal failure, with two women undergoing mechanical ventilation. There was 1 case of antenatal fetal death, with a total of 4 children being born, who were assessed on the Apgar scale with an average of 5 points.Conclusion. Timely diagnosis as well as ongoing therapeutic and preventive measures help to avoid complications during childbirth in pregnant women with TTP.

23 October 2022 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
VSV. G. Savchenko
V. G. Savchenko
ELE. A. Lukina
E. A. Lukina
EME. A. Mikhaylova
E. A. Mikhaylova
NTN. V. Tsvetaeva
N. V. Tsvetaeva
VLV. D. Latyshev
V. D. Latyshev
SLS. A. Lugovskaya
S. A. Lugovskaya
Introduction. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal disease of the blood system characterized by intravascular hemolysis, bone marrow dysfunction and an increased risk of thrombotic and organ complications.Aim — to provide relevant clinical recommendations for the provision of medical care to adults and children with PNH.Basic information. Experts from the National Hematological Society association which is focused on the promotion of hematology, transfusiology and bone marrow transplantation along with experts from the public organization, National Society of Pediatric Hematologists and Oncologists, have developed current clinical recommendations for providing medical care to adults and children with PNH. The recommendations address in detail the issues of etiology, pathogenesis, epidemiology, and clinical manifestations of the disease. Special attention is paid to the diagnosis, differential diagnosis, and treatment of PNH based on the principles of evidence.

27 January 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
VLV. D. Latyshev
V. D. Latyshev
ZFZ. T. Fidarova
Z. T. Fidarova
RPR. V. Ponomarev
R. V. Ponomarev
NTN. V. Tsvetaeva
N. V. Tsvetaeva
EME. A. Mikhaylova
E. A. Mikhaylova
EPE. N. Parovichnikova
E. N. Parovichnikova
Background. Paroxysmal nocturnal hemoglobinuria is a rare clonal disease of the hematopoietic system, with the key manifestations of hemolytic anemia, a high thrombosis rate, and bone marrow failure. Despite the high efficacy of C5‑inhibitors in intravascular hemolysis cessation, a significant proportion of patients remain anemic. Causes of a sub‑optimal response may include C3‑mediated extravascular (intracellular) hemolysis, residual intravascular hemolysis, or bone marrow failure.Aim. To analyze the results of pathogenetic therapy in patients with paroxysmal nocturnal hemoglobinuria.Materials and methods. The study included 55 patients with paroxysmal nocturnal hemoglobinuria receiving complement C5 inhibitors for at least 6 months. Results. Suboptimal hematological response was observed in 31/55 (56 %) patients. The most common cause of anemia in the partial response group was C3‑mediated extravascular hemolysis in 8/10 (80 %), while bone marrow failure predominated (57 %) in the minor response group.Conclusion. The study showed a high frequency of suboptimal response to pathogenetic therapy and necessity of ac‑curate determination of leading cause of persistent anemia in order to modify therapy or switch to other drugs.

11 May 2020 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
EMElena Mershina
Elena Mershina
OKOlga Kulikova
Olga Kulikova
RMRoman Myasnikov
Roman Myasnikov
ELE. A. Lukina
E. A. Lukina
Alexey MeshkovAlexey Meshkov
Alexey Meshkov
ODOxana M. Drapkina
Oxana M. Drapkina
This article presents the results of studies on high prevalence of left ventricular noncompaction (LVNC) in patients with secondary hemochromatosis (SH). We also included case reports of patients with SH and LVNC and compared imaging data using modified modern criteria for LVNC and molecular genetic testing (MGT). In patients with cardiac hemochromatosis, left ventricular noncompaction is noted, the nature of which is most likely secondary. In order to confirm this hypothesis, a prospective observational study, including family screening and MGT, is required.

29 September 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
MMMaria A. Mozdon
Maria A. Mozdon
RPRodion V. Ponomarev
Rodion V. Ponomarev
NTNina V. Tsvetaeva
Nina V. Tsvetaeva
ASAleksey V. Shabrin
Aleksey V. Shabrin
EEEvgeniya I. Ermachenkova
Evgeniya I. Ermachenkova
ELElena A. Lukina
Elena A. Lukina
RenduOslerWeber disease or hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease. It is characterized by vascular dysplasia with the formation of telangiectasias on the skin, mucous membranes of the respiratory and digestive tracts, arteriovenous malformations (AVMs) in the internal organs, which is manifested by bleeding. Diagnosis is based on Curacao criteria: recurrent and spontaneous nosebleeds, multiple telangiectases on the characteristic localizations, AVMs in one or more of the internal organs, a family history of HHT (i.e. first-degree relative who meets these same criteria for definite HHT). Therapy is aimed at preventing and stopping gastrointestinal, nosebleeds, correction of iron deficiency anemia. A promising method of therapy is the use of angiogenesis inhibitors, in particular bevacizumab. The article presents a description of a clinical case of HHT in a 49-year-old woman with telangiectisia on the mucous membrane of the tongue, gastrointestinal tract and liver AVMs.

1 October 2026 in Clinical oncohematology
Verified
Journal Article
Open access
PDF file
PVPolina Igorevna Vasilchenkova
Polina Igorevna Vasilchenkova
MFM. N. Finyakina
M. N. Finyakina
ONO. F. Nikulina
O. F. Nikulina
NTN. V. Tsvetaeva
N. V. Tsvetaeva
SKSergei research center for Kulikov
Sergei research center for Kulikov
ELE. A. Lukina
E. A. Lukina
BACKGROUND. Cold agglutinin disease (CAD) is an orphan hematologic disease characterized mainly by hemolytic anemia, increased titer of cold antibodies, and clonality of B-lymphocytes in peripheral blood or/and bone marrow. The role of T-cell population imbalance in CAD has not been studied due to the rarity of this disease and extreme heterogeneity of its clinical and laboratory manifestations. AIM. To analyze the pattern of T-lymphocyte subpopulation in CAD patients and to assess the information value of immune parameters for predicting the treatment efficacy and relapse risk. MATERIALS & METHODS. Over the period from 2020 to 2023, 128 patients with autoimmune hemolytic anemia were examined and treated at the National Research Center for Hematology, the CAD diagnosis was confirmed in 25 of them. The control group consisted of 57 healthy blood donors. RESULTS. Primary CAD patients showed significant decrease of naïve and central memory T-cells compared to similar subpopulations in donors. In 3 and 6 months after completion of immunosuppressive therapy with rituximab, CAD patients had a significant increase of T-helpers and cytotoxic T-lymphocytes as well as a decrease of T-regulatory cells. Among T-helper subpopulations, an increase in Th2 and Th17 cells was reported. The patients who achieved complete hematologic response prior to rituximab therapy, demonstrated a significant increase in Th22 cells. After 3 months of treatment, non-responders showed a drastic increase in cytotoxic T-lymphocytes followed by a decrease to baseline. CONCLUSION. The analysis of the phenotypic spectrum of T-cells demonstrated the difference between the count of naïve and central memory T-cells in CAD patients and healthy donors. This study revealed no significant association of these parameters with the response to immunosuppressive therapy. The only factor associated with achieving complete hematologic response to rituximab was a higher Th22 baseline level compared to donor population.